Up next

Autoplay

Dr. Karen Madsen: Exploring the Effects of Empagliflozin in Immune Cells from IBD Patients

0 Views • 08/18/25
Share
Side Effects
Side Effects
Subscribers
0

Empagliflozin (EMPA) is a drug that is used in the treatment of diabetes to help reduce levels of glucose in the blood. However, in large clinical trials, it has been shown to have beneficial effects on the heart and kidney by reducing inflammation.

Dr. Madsen and her team tested the ability of EMPA to reduce inflammation in an animal model of inflammatory bowel disease (IBD) and found it to be very effective at healing gut inflammation. They are now exploring EMPA’s effects in immune cells from IBD patients. Results from this study may provide evidence that EMPA could be used to treat IBD as a novel therapeutic agent.

Learn more about Crohn's and Colitis Canada's 2021 Grants-in-Aid of Research recipients at crohnsandcolitis.ca

Show more
0 Comments sort Sort By

Up next

Autoplay